BYSI

BeyondSpring, Inc. is a clinical-stage biopharmaceutical company headquartered in New York, New York, that focuses on developing innovative cancer therapies to improve clinical outcomes for patients with high unmet medical needs. The company's lead product candidate, plinabulin, is a selective immunomodulating microtubule-binding agent being developed for multiple cancer indications including non-small cell lung cancer and the prevention of chemotherapy-induced neutropenia. BeyondSpring's research approach targets both cancer cells and the tumor microenvironment, seeking to develop therapies that can work synergistically with existing cancer treatments. The company conducts clinical trials globally and has development partnerships in various regions including China. BeyondSpring's pipeline includes additional early-stage oncology programs exploring novel mechanisms of action. The company employs a team of experienced drug development professionals and collaborates with leading cancer research institutions to advance its clinical programs through regulatory approval pathways in the United States, China, and other markets.